Trofinetide receives FDA approval as first drug for Rett syndrome.
作者信息
Mughal Zaib Un Nisa, Ahmed Bisma, Rangwala Burhanuddin Sohail, Rangwala Hussain Sohail, Fatima Hareer, Ali Mirha, Farah Asma Ahmed
机构信息
Department of Medicine, Jinnah Sindh Medical University, Karachi, Sindh, Pakistan.
Department of Medicine, East Africa University, Boosaaso, Somalia.
出版信息
Ann Med Surg (Lond). 2024 Mar 18;86(5):2382-2385. doi: 10.1097/MS9.0000000000001896. eCollection 2024 May.
Abstract
摘要
相似文献
1
Trofinetide receives FDA approval as first drug for Rett syndrome.曲非奈肽获美国食品药品监督管理局批准，成为治疗雷特综合征的首款药物。
Ann Med Surg (Lond). 2024 Mar 18;86(5):2382-2385. doi: 10.1097/MS9.0000000000001896. eCollection 2024 May.
2
Trofinetide Receives FDA Approval as First Drug for Rett Syndrome.曲非奈肽获美国食品药品监督管理局批准，成为首个用于治疗雷特综合征的药物。
JAMA. 2023 Apr 11;329(14):1142. doi: 10.1001/jama.2023.4003.
3
Trofinetide in Rett syndrome: A brief review of safety and efficacy.曲非奈肽治疗瑞特综合征：安全性与疗效简要综述
Intractable Rare Dis Res. 2023 Nov;12(4):262-266. doi: 10.5582/irdr.2023.01060.
4
Trofinetide treatment for Rett syndrome: Lessons to learn.特罗氟尼定治疗雷特综合征：经验教训。
Med. 2024 Oct 11;5(10):1194-1196. doi: 10.1016/j.medj.2024.07.028.
5
A Double-Blind, Randomized, Placebo-Controlled Clinical Study of Trofinetide in the Treatment of Rett Syndrome.托吡酯治疗雷特综合征的双盲、随机、安慰剂对照临床研究。
Pediatr Neurol. 2017 Nov;76:37-46. doi: 10.1016/j.pediatrneurol.2017.07.002. Epub 2017 Jul 8.
6
Development of trofinetide for the treatment of Rett syndrome: from bench to bedside.用于治疗雷特综合征的曲非尼肽的研发：从实验室到临床应用
Front Pharmacol. 2024 Jan 22;14:1341746. doi: 10.3389/fphar.2023.1341746. eCollection 2023.
7
Trofinetide: First Approval.曲非奈肽：首次获批。
Drugs. 2023 Jun;83(9):819-824. doi: 10.1007/s40265-023-01883-8.
8
Trofinetide for Rett Syndrome: Highlights on the Development and Related Inventions of the First USFDA-Approved Treatment for Rare Pediatric Unmet Medical Need.用于雷特综合征的曲非奈肽：首个获美国食品药品监督管理局批准、用于满足罕见儿科未满足医疗需求的治疗药物的研发及相关发明要点
J Clin Med. 2023 Aug 4;12(15):5114. doi: 10.3390/jcm12155114.
9
Design and outcome measures of LAVENDER, a phase 3 study of trofinetide for Rett syndrome.LAVENDER研究（一项关于曲非尼肽治疗雷特综合征的3期研究）的设计与结果指标
Contemp Clin Trials. 2022 Mar;114:106704. doi: 10.1016/j.cct.2022.106704. Epub 2022 Feb 8.
10
Trofinetide-a new chapter in rett syndrome's treatment.曲非奈肽——雷特综合征治疗的新篇章。
Front Pharmacol. 2023 Nov 16;14:1284035. doi: 10.3389/fphar.2023.1284035. eCollection 2023.
本文引用的文献
1
Trofinetide Receives FDA Approval as First Drug for Rett Syndrome.曲非奈肽获美国食品药品监督管理局批准，成为首个用于治疗雷特综合征的药物。
JAMA. 2023 Apr 11;329(14):1142. doi: 10.1001/jama.2023.4003.
2
A comprehensive longitudinal study of magnetic resonance imaging identifies novel features of the Mecp2 deficient mouse brain.一项磁共振成像的综合纵向研究确定了 Mecp2 缺陷小鼠大脑的新特征。
Neurobiol Dis. 2023 May;180:106083. doi: 10.1016/j.nbd.2023.106083. Epub 2023 Mar 15.
3
Clinical EEG of Rett Syndrome: Group Analysis Supplemented with Longitudinal Case Report.雷特综合征的临床脑电图：分组分析并补充纵向病例报告
J Pers Med. 2022 Nov 29;12(12):1973. doi: 10.3390/jpm12121973.
4
Rett Syndrome and Duplication Syndrome: Disorders of MeCP2 Dosage.雷特综合征与重复综合征：MeCP2剂量紊乱疾病
Neuropsychiatr Dis Treat. 2022 Nov 29;18:2813-2835. doi: 10.2147/NDT.S371483. eCollection 2022.
5
Pain in Rett syndrome: a pilot study and a single case study on the assessment of pain and the construction of a suitable measuring scale.雷特综合征疼痛评估：一项初步研究和一个单病例研究，以及关于疼痛评估和合适测量量表构建的研究。
Orphanet J Rare Dis. 2022 Sep 14;17(1):356. doi: 10.1186/s13023-022-02519-y.
6
A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder.自闭症谱系障碍中分子信号转导功能障碍的观点及其临床意义和治疗。
Exp Brain Res. 2022 Oct;240(10):2525-2567. doi: 10.1007/s00221-022-06448-x. Epub 2022 Sep 5.
7
State-of-the-art therapies for Rett syndrome.治疗雷特综合征的最新疗法。
Dev Med Child Neurol. 2023 Feb;65(2):162-170. doi: 10.1111/dmcn.15383. Epub 2022 Sep 3.
8
Oral Feeding of an Antioxidant Cocktail as a Therapeutic Strategy in a Mouse Model of Rett Syndrome: Merits and Limitations of Long-Term Treatment.在雷特综合征小鼠模型中口服抗氧化剂鸡尾酒作为一种治疗策略：长期治疗的优点和局限性
Antioxidants (Basel). 2022 Jul 20;11(7):1406. doi: 10.3390/antiox11071406.
9
A Phase 1, Open-Label Study to Evaluate the Effects of Food and Evening Dosing on the Pharmacokinetics of Oral Trofinetide in Healthy Adult Subjects.一项评估食物和晚间给药对健康成年受试者口服托法替布药代动力学影响的 1 期、开放性研究。
Clin Drug Investig. 2022 Jun;42(6):513-524. doi: 10.1007/s40261-022-01156-4. Epub 2022 May 27.
10
MeCP2: The Genetic Driver of Rett Syndrome Epigenetics.MeCP2：雷特综合征表观遗传学的基因驱动因素。
Front Genet. 2021 Jan 21;12:620859. doi: 10.3389/fgene.2021.620859. eCollection 2021.
Zotero 插件